Metabolic Correction Research Articles

Metabolic correction of antioxidant status of blood using omega-3 polyunsaturated fatty acids in the treatment of psoriasis patients

Metabolic correction of antioxidant status of blood using omega-3 polyunsaturated fatty acids in the treatment of psoriasis patients

Мінеральний гомеостаз у тварин із урахуванням типологічних особливостей нервової системи за застосування кормової добавки

Мінеральний гомеостаз у тварин із урахуванням типологічних особливостей нервової системи за застосування кормової добавки

Clinical efficiency of exogenous L-arginine in patients with essential hypertension against the background of chronic obstructive pulmonary disease

Хроническое обструктивное заболевание легких (ХОЗЛ) и гипертоническая болезнь (ГБ) – одна из распространенных, ведущих и актуальных проблем практического здравоохранения. Цель работ ы – оценка клинической эффективности средства метаболической коррекции (Тивортин) в комплексном лечении больных хроническим обструктивным заболеванием легких при наличии гипертонической болезни. Материалы и методы. Обследовали 23 больных (основная группа) с диагнозом ГБ II стадии с уровнем артериальной гипертензии I–III степени и ХОЗЛ II стадии без клинически значимой сопутствующей патологии, средний возраст – 51,72 ± 1,22, с различным кардиоваскулярным риском, без адекватной систематической антигипертензивной терапии; 82,6 % – активные курильщики, индекс пачко-лет – 17,23 ± 2,69, на профессиональный фактор (производственный) указали 23,53 % обследованных. Все больные основной группы принимали L-аргинин аспартат в виде 4,2 % раствора внутривенно по 100 мл 1 раз в сутки (курс 10–12 дней) с последующим переходом на раствор для перорального применения по 10 мл 5 раз в сутки (курс 3 мес. ± 3 суток). Также обследовали (изначально и через 3 мес.) группу сравнения (n = 15, возраст – 49,15 ± 1,40 года), сопоставимую по клинико-демографическим показателям с основной группой. Обследованные из группы сравнения получали аналогичную традиционную терапию ГБ и ХОЗЛ без применения метаболитотропного препарата – экзогенного L-аргинина Тивортин. Диагностику ХОЗЛ и ГБ проводили на основании общепринятых критериев. Параметры качества жизни оценивали согласно «Краткого опросника оценки статуса здоровья» SF-36. Метаболизм глутатиона и состояние тиол-дисульфидного баланса изучали по содержанию окисленного и восстановленного глутатиона и активности ферментов – глутатион-S-трансферазы, глутатионредуктазы и глутатион пероксидазы в сыворотке крови. Содержание ST2, CASPASE-7 и CASPASE-9 в крови определяли с использованием соответствующих тест-систем ИФА. Результаты. Назначение L-аргинина способствовало подавлению оксидативного стресса и восстановлению тиол-дисульфидного баланса и, как результат вышеуказанных процессов, тормозило апоптоз в организме пациентов с коморбидностью. Уровень экспрессии белка ST2 после лечения пациентов с ГБ и ХОЗЛ Тивортином уменьшился в два раза, а компенсаторная возможность организма больного, которая заключается во включении кардиозащитного сигнального каскада предотвращения фиброза и ремоделирования сердца наиболее оптимальным путем будет реализована именно после проведения экспериментального лечения. Кроме регресса клинических симптомов, нормализации артериального давления и улучшения бронхиальной проходимости на фоне снижения уровня активности апоптотических маркеров, наблюдается восстановление качества жизни, как физического, так и психосоциального статуса. Выводы. Дополнительное назначение L-аргинина на фоне традиционной терапии ХОЗЛ и ГБ способствует более значимому и достоверному угнетению оксидативного стресса и восстановлению тиол-дисульфидного баланса и, как результат вышеуказанных процессов, тормозит интенсификацию процессов апоптоза у пациентов с указанной коморбидностью. Кроме регресса клинических симптомов, нормализации артериального давления и улучшения бронхиальной проходимости на фоне снижения уровня активности апоптотических маркеров, наблюдается достоверное восстановление качества жизни, как физического, так и психосоциального статуса.

Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features

Diabetes mellitus (DM) and chronic liver disease (CLD) are pathological conditions associated with each other and reaching epidemic proportions. There is a strong pathogenetic relationship of carbohydrate metabolism disorders and a number of CLD. Common mechanisms that provoke metabolic and autoimmune disorders in the development of various CLD, leading to steatosis, insulin resistance (IR), impaired glucose tolerance and the development of DM are described. Effective glycemic control can have a beneficial effect on the treatment of these patients, and, conversely, there is evidence of a positive effect of CLD therapy on carbohydrate metabolism. This review discusses the correction of carbohydrate metabolism in patients with CLD, the main groups of modern hypoglycemic drugs, mechanisms of their action, the impact on the physiology of the liver, the possibility of using each of these pharmacological groups in patients with impaired liver function. The modern approaches and possibilities of drug effects on the process of fibrogenesis in CLD, the effect of these drugs on carbohydrate metabolism are listed.

Long-Term Correction of Copper Metabolism in Wilson's Disease Mice with AAV8 Vector Delivering Truncated ATP7B.

Wilson's disease (WD) is an autosomal recessive disorder of copper metabolism caused by mutations in the ATP7B gene encoding a liver active copper transport enzyme. Gene therapy with adeno-associated virus (AAV) carrying full-length ATP7B, which is about 4.4 kb, was shown to rescue copper metabolism disorder in WD mouse model. However, due to its relatively large size, the AAV vector containing full-length ATP7B could be oversized for its packaging capacity, which could lead to inefficient packaging. To this purpose, we engineered a truncated ATP7B mutant (tATP7B) that is about 3.3 kb in length and used for AAV gene therapy for WD mice. In vitro test showed that the excretion of copper outside the cells could be achieved with tATP7B as efficient as the full-length ATP7B. In vivo delivery of tATP7B to WD mice by AAV8 vectors corrected their copper metabolisms and significantly rescued copper accumulation-related syndromes, including reduced urinary copper excretion, increased serum ceruloplasmin, and improved liver damages. Thus, our study demonstrated that AAV gene therapy based on truncated ATP7B is a promising strategy in the treatment of WD.

Extensive Metabolic Correction of Hurler Disease By Hematopoietic Stem Cell-Based Gene Therapy: Preliminary Results from a Phase I/II Trial

Extensive Metabolic Correction of Hurler Disease By Hematopoietic Stem Cell-Based Gene Therapy: Preliminary Results from a Phase I/II Trial

Diabetic involvement of the organ of vision

Diabetic involvements of the organ of vision may be divided into extraocular and ocular. The first group includes xanthelasma and eczemas of the eyelids, hordeolum, chalasion, blepharitis, acute and chronic conjunctivitis, conjunctival angiopathies, and pareses of the extraocular muscles. The second group in- cludes*iridal dystrophy, anterior uveitis, cataract, glaucoma, asteroid hyalosis, lipemia rctinalis, and diabetic retinopathy with its complications (hemophthalmia, detachment of the retina, and neovascu- lar glaucoma). Diabetic retinopathy is a late complication of diabetes mellitus. The author discusses the epidemiology of this condition, its pathophysiological and clinical features, classification, contribution of local factors to its pathogenesis, and possibilities of treatment and prevention of the disease. He emphasizes the leading role of optimal correction of carbohydrate metabolism as a means preventing diabetic retinopathy and of timely laser photocoagulation of the retina in its treatment.

Respiratory and metabolic acidosis correction with the ADVanced Organ Support system

BackgroundThe lung, the kidney, and the liver are major regulators of acid-base balance. Acidosis due to the dysfunction of one or more organs can increase mortality, especially in critically ill patients. Supporting compensation by increasing ventilation or infusing bicarbonate is often ineffective. Therefore, direct removal of acid may represent a novel therapeutic approach. This can be achieved with the ADVanced Organ Support (ADVOS) system, an enhanced renal support therapy based on albumin dialysis. Here, we demonstrate proof of concept for this technology.MethodsAn ex vivo model of either hypercapnic (i.e., continuous CO2 supply) or lactic acidosis (i.e., lactic acid infusion) using porcine blood was subjected to hemodialysis with ADVOS. A variety of operational parameters including blood and dialysate flows, different dialysate pH settings, and acid and base concentrate compositions were tested. Comparisons with standard continuous veno-venous hemofiltration (CVVH) using high bicarbonate substitution fluid and continuous veno-venous hemodialysis (CVVHD) were also performed.ResultsSixty-one milliliters per minute (2.7 mmol/min) of CO2 was removed using a blood flow of 400 ml/min and a dialysate pH of 10 without altering blood pCO2 and HCO3− (36 mmHg and 20 mmol/l, respectively). Up to 142 ml/min (6.3 mmol/min) of CO2 was eliminated if elevated pCO2 (117 mmHg) and HCO3− (63 mmol/l) were allowed. During continuous lactic acid infusion, an acid load of up to 3 mmol/min was compensated. When acidosis was triggered, ADVOS multi normalized pH and bicarbonate levels within 1 h, while neither CVVH nor CVVHD could. The major determinants to correct blood pH were blood flow, dialysate composition, and initial acid-base status.ConclusionsIn conclusion, ADVOS was able to remove more than 50% of the amount of CO2 typically produced by an adult human. Blood pH was maintained stable within the physiological range through compensation of a metabolic acid load by albumin dialysate. These in vitro results will require confirmation in patients.

Erythrocyte Encapsulated Thymidine Phosphorylase for the Treatment of Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy: Study Protocol for a Multi-Centre, Multiple Dose, Open Label Trial.

Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder which primarily affects the gastrointestinal and nervous systems. This disease is caused by mutations in the nuclear TYMP gene, which encodes for thymidine phosphorylase, an enzyme required for the normal metabolism of deoxynucleosides, thymidine, and deoxyuridine. The subsequent elevated systemic concentrations of deoxynucleosides lead to increased intracellular concentrations of their corresponding triphosphates, and ultimately mitochondrial failure due to progressive accumulation of mitochondrial DNA (mtDNA) defects and mtDNA depletion. Currently, there are no treatments for MNGIE where effectiveness has been evidenced in clinical trials. This Phase 2, multi-centre, multiple dose, open label trial without a control will investigate the application of erythrocyte-encapsulated thymidine phosphorylase (EE-TP) as an enzyme replacement therapy for MNGIE. Three EE-TP dose levels are planned with patients receiving the dose level that achieves metabolic correction. The study duration is 31 months, comprising 28 days of screening, 90 days of run-in, 24 months of treatment and 90 days of post-dose follow-up. The primary objectives are to determine the safety, tolerability, pharmacodynamics, and efficacy of multiple doses of EE-TP. The secondary objectives are to assess EE-TP immunogenicity after multiple dose administrations and changes in clinical assessments, and the pharmacodynamics effect of EE-TP on clinical assessments.

Correction of metabolism and microbiocenosis in pregnant sows

Correction of metabolism and microbiocenosis in pregnant sows

Possibilities of blood pressure and metabolic disorders correction by using diet programs in patients with overweight and obesity

Hypertension is one of the most important risk factors of cardiovascular disease. The close relationship of overweight and obesity with high blood pressure is recognized by most experts. Recently, epidemiological studies have seen a steady increase in the frequency of arterial hypertension, which is associated with the pandemic of obesity and its attendant conditions - metabolic syndrome and diabetes. In this regard, it becomes clear that the correction of body weight plays a key role among the modified risk factors. According to the latest recommendations of The American Heart Association and The European Society of Cardiology, all patients with hypertension should follow dietary recommendations. There are a huge number of nutritional recommendations that potentially lower blood pressure. Such as restriction of salt intake, increased level of potassium in the diet, of fiber consumption of polyunsaturated fatty acids. Some of the recommendations are combined into dietary patterns. One of these is vegetarianism. There are also diets that have shown their effectiveness in reducing blood pressure. These include the Mediterranean Diet, the Northern Diet, the DASH Diet. The purpose of this review is to consider the popular dietary approaches that reduce blood pressure and the evidence of their effectiveness.

PS1221 LONG‐TERM EFFICACY AND SAFETY OF INOTERSEN FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: NEURO‐TTR OPEN‐LABEL EXTENSION 2‐YEAR UPDATE

Background:Hereditary transthyretin amyloidosis (hATTR) is a rare protein misfolding disorder that causes progressive and debilitating polyneuropathy. A randomized, controlled phase 3 trial (NEURO‐TTR; NCT01737398) demonstrated efficacy and safety of inotersen in patients with hATTR polyneuropathy (Benson 2018 NEJM).Aims:To provide an update on the long‐term efficacy and safety of inotersen, an antisense oligonucleotide inhibitor of transthyretin protein production, in patients with hereditary transthyretin amyloidosis (hATTR) with polyneuropathy.Methods:Patients who completed NEURO‐TTR were eligible to enroll in an ongoing open‐label extension (OLE) study (NCT02175004). We report an update on the long‐term efficacy and safety of inotersen in patients with hATTR polyneuropathy after 24 months in the OLE. Assessments included modified Neuropathy Impairment Score +7 neurophysiologic tests composite score (mNIS+7), Norfolk Quality of Life–Diabetic Neuropathy questionnaire total score (Norfolk QoL‐DN), Short Form 36 Health Survey version 2 (SF‐36v2) physical component summary (PCS), and safety monitoring.Results:Of 139 patients who completed NEURO‐TTR, 135 (97.1%) enrolled in the OLE. As of 5/31/2018, some patients were ongoing but had not yet completed 24 months in the OLE, and longest inotersen exposure in both studies was 5.2 years. Patients who switched from placebo to inotersen in the OLE demonstrated slowing of neurologic disease progression by mNIS+7 and Norfolk QoL‐DN as early as 6 months after starting inotersen (mean change from OLE baseline to month 6/year 2: 6.22/5.08 for mNIS+7 and 0.54/2.26 for Norfolk QoL‐DN). Patients who received inotersen for 39 months (15 months NEURO‐TTR + 24 months OLE) continued to show benefit (mean change from OLE baseline to year 2: 11.18 for mNIS+7 and 5.22 for Norfolk QoL‐DN). Patients who continued inotersen also showed stabilization of health‐related quality of life measured by SF‐36v2 PCS. No evidence of increased risk for grade 4 thrombocytopenia or severe renal events has been observed with increased exposure duration; no new safety concerns have been identified.Summary/Conclusion:In the OLE, inotersen improved, halted, or slowed progression of hATTR polyneuropathy, with greater stabilization observed in patients who initiated inotersen earlier.

PS1220 EX‐VIVO HEMATOPOIETIC STEM CELL GENE THERAPY (GT) FOR MUCOPOLYSACCHARIDOSIS TYPE I HURLER (MPSIH): PRELIMINARY RESULTS FROM A PHASE I/II CLINICAL STUDY

Background:MPSIH is a lysosomal storage disease caused by α‐L‐iduronidase (IDUA) deficiency that is associated with progressive multisystem morbidity including neurodevelopmental deterioration and severe orthopedic manifestations, leading to death in early childhood. Current therapeutic strategies include enzyme replacement therapy and allogeneic hematopoietic stem cell transplantation (HSCT), which however show limitations in preventing neurodevelopmental and orthopedic complications. Transplantation of genetically‐engineered autologous hematopoietic stem and progenitor cells (HSPC) is an attractive treatment option for MPSIH thanks to the possibility to obtain supraphysiologic levels of the missing enzyme in the hematopoietic progeny, thus allowing for increased cross‐correction.Aims:We recently opened a phase I/II clinical trial (NCT03488394) in children affected by MPSIH aimed at evaluating safety, tolerability and efficacy of the transplantation of autologous, IDUA lentiviral (LV)‐transduced CD34+ cells in MPSIH patients undergoing myeloablative conditioning.Methods:The study foresees the enrollment of 6 patients who lack a non‐heterozygous HLA‐matched donor and display an IQ/DQ>70. Primary endpoints of safety include: overall survival, hematological engraftment and safety of drug product (DP) administration. Primary endpoint of efficacy is represented by IDUA activity in peripheral blood up to supraphysiologic levels at 1 year post‐gene therapy (GT). Treatment impact on nervous system, skeleton and other target organs is assessed by clinical and radiologic parameters, as well as by disease‐specific biomarkers.Results:By the submission deadline, two patients (24 and 14 months old) were treated and have a follow‐up of 7 and 1.5 months, respectively. Autologous HSPC were harvested after mobilization with G‐CSF and Plerixafor; the procedure was uneventful and resulted in cryopreserved DP of 24 and 14 million CD34+ cells/kg, respectively. Transduction efficiency in the drug products was above 80% using an optimized transduction protocol that preserved engraftment potential of ex vivo‐cultured HSPC in preclinical models. No adverse events related to DP infusion were recorded. Hematopoietic engraftment was fast in both patients; neutrophil engraftment occurred on day +17 and +22, respectively; platelet engraftment at day+15 with counts never falling below 30.000/ul in both patients. Importantly, both patients reached supraphysiologic levels of IDUA by day+14 that stabilized around 10 fold above the mean of the normal range, along with an in vivo vector copy number ranging from 2 to 4 in multiple hematopoietic lineages. At the 6 month follow‐up of patient 1, stable IDUA activity was detected in the cerebrospinal fluid, and urinary GAGs normalized. A third patient has been successfully mobilized resulting in a cryopreserved DP of 13 million CD34+ cells/kg and will be treated shortly. Other patients are currently under evaluation.Summary/Conclusion:Preliminary clinical results indicate that our optimized transduction protocol allows efficient HSPC transduction without compromising their engraftment potential. Treated patients showed rapid hematopoietic recovery, supraphysiologic IDUA levels in the peripheral blood and metabolic correction of the MPSI‐H enzyme defect in critical target tissues. Long term‐follow up and treatment of further patients are necessary to confirm that IDUA supraphysiologic levels result in improvement of neurological and orthopedic outcome as compared to allogeneic HSCT.

Клинические рекомендации по коррекции углеводного обмена и сахароснижающей терапии у больных сахарным диабетом 2 типа и хронической болезнью почек

Клинические рекомендации по коррекции углеводного обмена и сахароснижающей терапии у больных сахарным диабетом 2 типа и хронической болезнью почек

NUTRITION FOR CORRECTING METABOLISM DISORDERS OF THE JOINT-LIGAMENT SYSTEM IN PHYSICALLY ACTIVE PEOPLE

Aim. The article deals with developing and assessing the efficiency of a complex nutritional support program for the joint-ligament system in athletes and physically active people. Materials and methods. The clinical evidence of biologically active substance (BAS) efficiency and functional orientation was obtained from the representative group of people with knee-joint osteoarthrosis. The main group of participants received a BAS complex with synergistic properties in terms of metabolism correction during osteoarthrosis: BAS 1 – 2 pills, BAS 2 – 1 capsule (2 times per day, 12 weeks), and BAS 3 – 1 capsule (2 times per day, 8 weeks). Nonsteroidal anti-inflammatory drugs were also prescribed to participants from the main and control groups. We used the general and special methods for assessing the quality and functional properties of specialized products. Knee joints were studied by using the Lequesne index (scores) characterizing pain syndrome, maximal distance, and daily movement activity. The intensity of pain syndrome was assessed with the visual analog scale (VAS, in mm). Results. We provided a scientific justification for the qualitative and quantitative content of BAS recipes for complex nutritional support of the joint-ligament system: BAS 1 – chondroprotective orientation; BAS 2 – an optimal source of minerals and vitamins; BAS 3 – polyunsaturated fatty acids. The results obtained revealed that specialized products improve the movement activity of participants with osteoarthrosis and significantly decrease pain syndrome (36 %). Apart from a chondroprotective effect such nutrition provides an anti-inflammatory effect and allows decreasing the intake of Nonsteroidal anti-inflammatory drugs in the absence of side effects. We revealed an insignificant number of disease recurrence – 6.7% (in the control group – 36.5 %) and established the mechanisms of such an influence. Conclusion. The application of biologically active complexes could serve as a reliable means of preventing and treating the diseases of the joint-ligament system, providing physical performance, and preserving health in athletes and physically active people.

The investigation of the influence which is done as a result of macleaya cordata and biologically active additives on the carbohydrate metabolism in pigs

Pork production plays a significant role in meat balance of Ukraine. High productivity of pigs is accompanied with increased intensity of metabolic processes and intense functional activity of all organs and systems, which requires additional support. To grow a healthy livestock, it is necessary to use preparations and biologically active forage plant additives that help a body to realize productive qualities, fight against various pathogens, but do not harm the animal body and are safe in the production of meat products for human nutrition. The influence of phytobiotic of the cardiac macleaya (Macleáya cordáta R. Br.) has been investigated separately and in combination with vegetable additives (buckwheat, ground onion and buckwheat husks) as a source of flavonoids on the physiological state and carbohydrate metabolism of pigs. It has been determined that application of only macleaya supplements to the 30 and 60 days of studies leads to an increase in the number of erythrocytes by 16.7% and 23.2% (P < 0.05) and hemoglobin concentration by 30.7% and 37.9% (P < 0.01), as well as activation of anaerobic glycolysis, as evidenced by a significant increase in glucose concentration by 96.4–48.0% (P < 0.01), lactate by 71.4–55.2%, (P < 0.01) and activity of lactate dehydrogenase at 18.6–29.4% (P < 0.05) and reduction of pyruvate content by 34.0–13.4% (P < 0.01) and activity of alkaline phosphatase – by 66.2% and 76.8% (P < 0.01) in the corresponding terms of research. While using macleaya with green buckwheat, buckwheat and onion husks, the hematological parameters and parameters of carbohydrate metabolism were at the level of the control group, confirming the significant decrease in the concentration of glucose and lactate compared with the control and shift ratio lactate / pyruvate towards pyruvate. This fact suggests that bioflavonoids, which are part of plant additives, have not only antioxidant properties, but also serve as a correction and stabilizer of carbohydrate metabolism and mitigate the side hypoxic effects of alkaloids of phytobiotic of the macleaya cordata.

Physical therapy of the early non-motorized violations to slow the progression of Parkinson's disease

The authors developed and applied the original complex of innovative combined physical therapy of non-motor manifestations of the early stages of Parkinson's disease to slow its progression. Applied concomitant treatments affect some parts of the etiology and pathogenesis of non-motor manifestations of Parkinson's disease. In particular, hirudotherapy restores the rheological properties of blood without side effects characteristic of known anticoagulants; helps to restore tissue trophism, in particular the brain. Nutritional correction prevents the development of digestive disorders. The main principles of such nutrition were: 1. The role of antioxidant saturation of the diet for the correction of metabolism. 2. The value of increasing the number of "ballasts" in the diet. 3. "Free mode" of food intake (at the request of the organism), taking into account the human biorhythms (daily, seasonal and psychological). 4. The need for periodic short-term fasting - as a method of cleansing the body. 5. The need for separate power. Manual therapy in the variant proposed by the authors prevents the vertebral component of the destructive processes in the brain. After the use of combined physical therapy, an improvement in the objective state of patients with Parkinson's disease was noted. According to the study, non-motor symptoms on the scale of autonomic disorders and non-motor symptoms (NMSS) were statistically significantly less pronounced in all patients examined in the group of patients using the developed complex of physical therapy compared to the group of patients without using the developed complex of physical therapy. Considering the improvement of the objective state of patients after the applied physical treatment, we can recommend the indicated therapeutic technique for the complex treatment of early non-motor manifestations of Parkinson's disease, slowing its progression and improving the effectiveness of existing modern treatment regimens of the studied pathology.

Modern opportunities for the burn shock resuscitation

Burn shock is characterized by significant disturbances of central hemodynamic, the presence of microcirculatory disorders due to primary hypovolemia, stress reaction, mass release of inflammatory response mediators, the development of all types of hypoxia, sharp changes in the acid-base state, blood coagulation, dysproteinaemic changes, electrolyte imbalance and quickly leads to the organ dysfunction and multiple organ failure. In this regard, infusion therapy is important in the treatment of burn patients, aimed at blood rheology improving, tissues microcirculation, acidosis correction. Significant homeostatic disturbances during the burn shock acutely determine the infusion solutions choice problem for the hemodynamic disturbance’s correction. The infusion solutions characteristics of for the correction of hemodynamic disturbances during burn shock have been given. Volume deficit recovery for tissue perfusion support and metabolic acidosis correction can be achieved with crystalloid and colloid solutions. Among plasma substitutes, these are low molecular weight hydroxyethyl starch which replaced dextran and native proteins (albumin, plasma). But crystalloids cause swelling. Dextran are not applied now. Albumin transfusion is indicated only for hypoproteinaemia, and plasma for the coagulation factors deficiency. The role of Rheosorbilact in the correction of hypovolemia and metabolic acidosis in patients with burn disease is shown. The presence in clinical practice of domestic polyionic multifunctional solutions of Rheosorbilact gives a positive impetus to the development of new infusion therapy methods.

Use of chloride-bicarbonate sodium mineral water ‘Karachinskaya’ in patients with non-alcoholic fatty liver disease

The aim of the study was to determine for patients with non-alcoholic fatty liver disease (NAFLD) the possibilities and effectiveness of the course use of chloride-bicarbonate sodium mineral water (MW) (by the example of MW Karachinskaya). A total of 76 patients (20 women and 56 men) with NAFLD aged 42 to 72 years (mean age 59.4 ± 1.2 years) were examined. MV was taken in 200 ml in 8, 10, 12, 15 and 17 hours (5 times a day, in a volume of 1,000 ml), room temperature (18-20 °C). The course of treatment was 10 days. In the dynamics of treatment, lipid spectrum parameters were evaluated: total cholesterol, triglycerides, high, low and very low density lipoprotein cholesterol, atherogenic index. The results obtained allow us to draw the following conclusions. 1. In patients with NAFLD observed by us, comorbid pathology is observed at least 3-4 diseases of internal organs are registered at the same time. The most frequently detected pathology of the cardiovascular system and disorders of carbohydrate metabolism. 2. The vast majority of patients revealed lipid metabolism disorders. The most significant disorders were characterized by increased levels of total cholesterol. 3. The inclusion of the 10-day drinking course of the chloride-bicarbonate sodium MW Karachinskaya’ contributes to the correction of lipid metabolism. The identified cholesterol-lowering effect of MW Karachinskaya' with mild and moderate hypercholesterolemia allows recommending it for non-pharmacological correction of elevated total cholesterol, which is currently considered as an established risk factor for IHD and arterial hypertension.

Enzyme Replacement therapy with Pegademase Bovine for Human Adenosine Deaminase Primary Immunodeficiency

Adenosine deaminase deficiency (ADA) represents an immune system disorder producing abnormalities in humoral and cellular immune responses due to the lack of adenosine deaminase (ADA) enzyme. PEG-ADA therapy tries to counteract ADA deficiency by conjugates conformed of numerous mono-methoxy polyethyleneglycol chains linked non-covalently, and ADA enzymes, which are bound by lysine residues. PEG-ADA protects from any proteolytic attack, and presentation of antigens, increasing their lifespan within the organism. Enzyme replacement therapy with PEGylated ADA provides metabolic correction and improvement in immune function and clinical parameters. Its effectiveness is confirmed by the increase of B and T lymphocytes in questionable time ranges.